ARIAD
Pharmaceuticals, Inc. ARIA today announced twelve-month
follow-up data from the pivotal PACE trial of ponatinib,
its investigational BCR-ABL inhibitor, in heavily pretreated patients
with resistant or refractory chronic myeloid leukemia (CML) or
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
The study now shows that 56 percent of chronic-phase CML patients in the
trial, including 70 percent of patients with a T315I mutation, achieved
a major cytogenetic response (MCyR), the primary end-point for
chronic-phase CML patients.
The data are being featured today at 4:30 p.m. (ET) in an oral
presentation at the 54th Annual Meeting of the American Society of
Hematology (ASH) being held in Atlanta,
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in